Susanna S. Hemphill

Design, synthesis, and structure-activity relationship of novel orally efficacious pyrazole/sulfonamide based dihydroquinoline gamma-secretase inhibitors.

H. Sham, T. Yednock, M. Bova, 2009, Bioorganic & medicinal chemistry letters.

Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease

R. Motter, D. Kholodenko, R. Barbour, 2010, Alzheimer's Research & Therapy.

Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitor

R. Motter, D. Kholodenko, H. Sham, 2013, Journal of medicinal chemistry.

Pharmacokinetic and pharmacodynamic investigation of ELND006, a novel APP-selective gamma-secretase inhibitor, on amyloid-β concentrations in the brain, CSF and plasma of multiple nonclinical species following oral administration

R. Motter, D. Kholodenko, K. Hu, 2010, Alzheimer's & Dementia.

Design, synthesis and structure-activity relationship of novel [3.3.1] bicyclic sulfonamide-pyrazoles as potent γ-secretase inhibitors.

H. Sham, M. Bova, J. Sauer, 2011, Bioorganic & Medicinal Chemistry Letters.

Amino-caprolactam γ-secretase inhibitors showing potential for the treatment of Alzheimer's disease.

M. Bova, J. Sauer, G. Basi, 2011, Bioorganic & medicinal chemistry letters.

N-Bridged bicyclic sulfonamides as inhibitors of gamma-secretase.

H. Sham, M. Bova, J. Sauer, 2009, Bioorganic & medicinal chemistry letters.

Discovery of (R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo[4,3-c]quinoline (ELND006) and (R)-4-cyclopropyl-8-fluoro-5-(6-(trifluoromethyl)pyridin-3-ylsulfonyl)-4,5-dihydro-2H-pyrazolo[4,3-c]quinoline (ELND007): metabolically stable γ-secretase Inhibitor

R. Motter, D. Kholodenko, H. Sham, 2013, Journal of medicinal chemistry.